ProQR Therapeutics (PRQR) Enterprise Value (2021 - 2025)
ProQR Therapeutics (PRQR) has disclosed Enterprise Value for 5 consecutive years, with -$107.6 million as the latest value for Q4 2025.
- Quarterly Enterprise Value rose 32.62% to -$107.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$107.6 million through Dec 2025, up 32.62% year-over-year, with the annual reading at -$107.6 million for FY2025, 32.62% up from the prior year.
- Enterprise Value hit -$107.6 million in Q4 2025 for ProQR Therapeutics, up from -$159.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$96.7 million in Q4 2022 to a low of -$214.5 million in Q4 2021.
- Historically, Enterprise Value has averaged -$141.3 million across 5 years, with a median of -$128.0 million in 2023.
- Biggest five-year swings in Enterprise Value: skyrocketed 54.93% in 2022 and later plummeted 32.33% in 2023.
- Year by year, Enterprise Value stood at -$214.5 million in 2021, then surged by 54.93% to -$96.7 million in 2022, then tumbled by 32.33% to -$128.0 million in 2023, then dropped by 24.77% to -$159.7 million in 2024, then skyrocketed by 32.62% to -$107.6 million in 2025.
- Business Quant data shows Enterprise Value for PRQR at -$107.6 million in Q4 2025, -$159.7 million in Q4 2024, and -$128.0 million in Q4 2023.